Efficacy of naltrexone in smoking cessation: A preliminary study and an examination of sex differences
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
This double-blinded, placebo-controlled trial evaluated the efficacy of naltrexone as an adjunct to standard smoking cessation treatment. Participants (N = 110) were adult male and female nicotine-dependent smokers who expressed interest in quitting smoking. All subjects received six sessions of behavioral counseling (1 hr/session for 6 weeks), and 1 month of the nicotine patch (21 mg for the first 2 weeks, 14 mg the third week, 7 mg the fourth week). Subjects were randomly assigned to the naltrexone or placebo group. The naltrexone group started at 25 mg daily for 3 days prior to the quit date, and increased to 50 mg/day on the quit date and following 8 weeks. At the end of medication treatment, the naltrexone group had better quit rates versus the placebo group (48% quit on naltrexone vs. 41% on placebo), but this difference was not statistically significant. However, men and women differed on several measures: in the placebo group, women had significantly lower quit rates than men (39% vs. 67%, p<.05), but in the naltrexone group, women had quit rates comparable with those of men (58% vs. 62%, p = ns). Further examination revealed that naltrexone significantly reduced men's and women's cessation-related weight gain and selectively reduced women's urge to smoke to relieve negative affect and withdrawal. The results suggest continued examination of naltrexone as an adjunct in smoking cessation, particularly in female smokers, who have historically shown worse outcomes with traditional treatment methods.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Practice Guideline: Otitis Media with Effusion (Update)
Rosenfeld, R. M., Shin, J. J., Schwartz, S. R., Coggins, R., Gagnon, L., Hackell, J. M., Hoelting, D., Hunter, L. L., Kummer, A. W., Payne, S. C., et al. (2016) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599815623467 · Cited by 2,006
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Signs and Symptoms of Tobacco Withdrawal
Hughes, J. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800030107013 · Cited by 1,669
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 1×
“Quit rates are significantly improved with use of FDA-approved medications, such as nicotine replacement or bupropion, either alone or in combination (Fiore et al., 2000; Jorenby et al., 1999).”
BackgroundCox, L. S., Tiffany, S. T., & Christen, A. G. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200020032051 · Cited by 1,188
Smoking withdrawal dynamics in unaided quitters.
Piasecki, T. M., Niaura, R., Shadel, W. G., Abrams, D., Goldstein, M., Fiore, M. C., & Baker, T. B. (2000) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.109.1.74 · Cited by 262 · cited 1×
“The expanded MWS included 14 total items scored on five-point Likert scales (ratings 0–4) with several additional items included so that two subscales, a withdrawal negative affect scale and a sleep/fatigue scale, could be computed (Piasecki et al., 2000).”
BackgroundSelf-citationKlesges, R. C., Somes, G., Pascale, R. W., Klesges, L. M., Murphy, M., Brown, K., & Williams, E. (1988) · Health Psychology · doi:10.1037/0278-6133.7.5.387 · Cited by 119
Cited by
Dopamine in Drug Abuse and Addiction: Results of Imaging Studies and Treatment Implications
Volkow, N. D., Fowler, J. S., Wang, G.-J., Swanson, J. M., & Telang, F. (2007) · Archives of Neurology · doi:10.1001/archneur.64.11.1575 · Cited by 605
Interventions for preventing weight gain after smoking cessation
Farley, A. C., Hajek, P., Lycett, D., & Aveyard, P. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006219.pub3 · Cited by 334
Past major depression and smoking cessation outcome: A systematic review and meta-analysis update
Hitsman, B., Papandonatos, G. D., McChargue, D. E., DeMott, A., Herrera, M. J., Spring, B., Borrelli, B., & Niaura, R. (2013) · Addiction · doi:10.1111/add.12009 · Cited by 162
Self-citationSmoking cessation interventions for smokers with current or past depression
van der Meer, R. M., Willemsen, M. C., Smit, F., & Cuijpers, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006102.pub2 · Cited by 159
Berrendero, F., Robledo, P., Trigo, J. M., Martín-García, E., & Maldonado, R. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.02.006 · Cited by 140
“In this sense, the dose of 50mg f naltrexone appears to be more effective for smoking cessation n female smokers when given alone (King et al., 2006) or in comination with nicotine replacement therapy (Byars et al.”
Method
Metadata
- Authors
- King, A., de Wit, H., Riley, R., Cao, D., Niaura, R., & Hatsukami, D.
- Venue
- Nicotine & Tobacco Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-10-01
- Volume
- 8
- Issue
- 5
- Pages
- 671-682
- ISSN
- 1462-2203 (ISSN-L)
- 1469-994X
- OpenAlex
- W1986846191
- Cited by
- 87
- References
- 7
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of naltrexone in smoking cessation: A preliminary study and an examination of sex differences. https://app.cochat.ai/papers/10.1080/14622200600789767
- The paper
- King, A., de Wit, H., Riley, R., Cao, D., Niaura, R., & Hatsukami, D. (2006). Efficacy of naltrexone in smoking cessation: A preliminary study and an examination of sex differences. Nicotine & Tobacco Research. https://doi.org/10.1080/14622200600789767
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.